Alert in from Fido on IPIX .. Form 424B2 Inn

Alert in from Fido on IPIX ..


Form 424B2 Innovation Pharmaceutica
10K WIZARD 10:03 AM ET 11/13/2017
http://archive.fast-edgar.com/20171113/AIZCL2...PQZZ27Z292

Filed on: November 13, 2017

24 Pages ..


===

Filed pursuant to Rule 424(b)(2)

Registration Statement No. 333-220419



PROSPECTUS SUPPLEMENT

(To Prospectus Dated September 21, 2017)



$28,499,720



INNOVATION PHARMACEUTICALS INC.



Class A Common Stock



Pursuant to this prospectus supplement and the accompanying prospectus, we are offering up to $28,499,720 of shares of our Class A common stock, par value $0.0001 per share (“common stock”) to Aspire Capital Fund, LLC (“Aspire Capital”) under a common stock purchase agreement entered into on September 6, 2017 (the “Purchase Agreement”).



The shares of common stock offered under the Purchase Agreement include (i) 300,000 shares of common stock previously issued to Aspire Capital in consideration for entering into the Purchase Agreement (the “Commitment Shares”), and (ii) additional shares of common stock, which may be sold from time to time to Aspire Capital until and including September 7, 2020, with an aggregate offering price of up to $30 million, of which approximately $1.5 million has previously been sold as of the date of this prospectus supplement (the “Purchase Shares”). The purchase price for any additional Purchase Shares will be based upon one of two formulas set forth in the Purchase Agreement depending on the type of purchase notice we submit to Aspire Capital from time to time.



Our common stock is currently quoted on the OTCQB under the symbol “IPIX.” On November 8, 2017, the last reported sales price of our common stock on the OTCQB was $0.72 per share.



Investing in our securities involves a high degree of risk. You should read “Risk Factors” beginning on page S-3 of this prospectus supplement and the reports we file with the Securities and Exchange Commission pursuant to the Securities Exchange Act of 1934, as amended, incorporated by reference in this prospectus supplement, to read about factors to consider before purchasing our securities.



Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.


The date of this prospectus supplement is November 13, 2017.